82 results about "Premature birth" patented technology

The present invention provides methods of treating one or more complications of premature birth suffered by premature infants, comprising administering to the premature infant umbilical cord blood stem cells and, optionally, placental stem cells. The present invention also provides methods of combining and administering, and compositions comprising, umbilical cord blood stem cells, particularly autologous cord blood cells, and placental stem cells for the treatment of premature infants.

A combination of an anti-androgenic gestagen at a daily dose of from an ovulation-inhibiting dose up to at most twice the ovulation-inhibiting dose and from 0.1 to 10 mg of (6S)-5-methyltetrahydrofolate are used to produce a pharmaceutical preparation for therapeutically treating endometriosis while simultaneously reducing therapy side effects including the negative effect on bone density and / or bone metabolism, reducing the risk of osteoporosis and, in the event of pregnancy, reducing the risk of congenital malformations, such as medullary tube defects, cleft lip, cleft jaw, or cleft palate, and the risk of pregnancy complications, such as detachment of the placenta and premature birth. The preparation is suitable for long-term administration, which continues daily for at least 169 days to at least two years.

The present invention relates to solid oral formulations comprising a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one-O-methyloxime, and / or an active metabolite thereof, and the use of said formulations in the treatment and / or prevention of preterm labor, premature birth, dysmenorrhea and embryo implantation failure due to uterine contractions. The present invention is furthermore related to processes for their preparation.

Methods for diagnosing risk of miscarriage and / or premature birth, foetal abnormalities, cancer (e.g. prostate cancer) and inflammatory disease (e.g. rheumatoid arthritis) are disclosed which involve determining abnormal levels of macrophage inhibitory cytokine-1 (MIC-1) in a body sample or, otherwise, determining the presence of a MIC-1 variant protein. Also disclosed are methods for reducing the risk of miscarriage and / or premature birth in pregnant subjects, and methods for treatment of inflammatory disease and / or cancer.

A thermal and moisture barrier device for use with a specialized heating and humidifying apparatus in the care of extremely premature neonatal infants. The thermal and moisture barrier comprises a collapsible and substantially flexible cover which defines an enclosed volume, large enough to accommodate an extremely premature neonatal infant. At least one flexible opening is located on a portion of the cover which communicates with the enclosed volume. A diaphragm provides closure of the flexible openings. The diaphragm is a resiliently flexible sheet extending across the opening and has slits.

Described herein are biomarkers, such as protein biomarkers, which are diagnostic of and predictive for complications that result from an in utero encounter, such as an infection by the fetus, that can lead to premature birth (PTB). The biomarkers can be used to identify fetuses and newborns at risk for complications of PTB, such as (Early Onset Neonatal Sepsis) EONS, intra-ventricular hemorrhage (IVH) and other poor outcomes.

The invention relates to a combined assay kit for premature birth of a pregnant woman and fetal membrane premature rupture, which comprises a premature birth and fetal membrane premature rupture immunochromatographic assay test strip or comprises a premature birth immunochromatographic assay test strip and a fetal membrane premature rupture immunochromatographic assay test strip. More preferably, the combination mat and the nitrocellulose membrane of the premature birth immunochromatographic assay test strip are respectively provided with a premature birth assay immunolabelling antibody and a premature birth assay antibody; the combination mat and the nitrocellulose membrane of the fetal membrane premature rupture immunochromatographic assay test strip are respectively provided with a fetal membrane premature rupture assay immunolabelling antibody and a fetal membrane premature rupture assay antibody, or the immunolabelling antibodies and the antibodies are respectively coated onto the combination mats and the nitrocellulose membranes of the premature birth and fetal membrane premature rupture immunochromatographic assay test strip. The combined assay kit for the premature birth of the pregnant woman and the fetal membrane premature rupture is capable of simultaneously diagnosing the premature birth and the fetal membrane premature rupture through primary sampling, is simple and convenient in application, and further, is capable of improving the accuracy of premature birth diagnosis. A powerful basis is provided for the next accurate treatment by combined assay results. The combined assay kit for the premature birth of the pregnant woman and the fetal membrane premature rupture is suitable for popularization and application in a large scale.

A system and method for stabilizing an incontinent cervix during pregnancy are described. A system may include a nesting portion designed to surround the cervix without applying pressure to the cervix, while supporting the uterus in opposition to the weight of the developing fetus to prevent untimely effacement and dilatation of the cervix; thereby reducing the risk of premature birth and its consequence.

The present invention relates to novel pyrrolidine derivative of formula (I), its geometrical isomers, its optically active forms as enantiomers, diastereomers, mixtures of these and its racemate forms, as well as salts thereof, wherein R1 is selected from the group comprising or consisting of H and C1-C6-alkyl, for the prevention and / or treatment of preterm labor, premature birth or dysmenorrhea.

The present invention provides methods of treating one or more complications of premature birth suffered by premature infants, comprising administering to the premature infant umbilical cord blood stem cells and, optionally, placental stem cells. The present invention also provides methods of combining and administering, and compositions comprising, umbilical cord blood stem cells, particularly autologous cord blood cells, and placental stem cells for the treatment of premature infants.

The present invention is related to pyrrolidine derivatives of formula (I). Saidcompounds are preferably for use as pharmaceutically active compounds. Specifically, pyrrolidine derivatives of formula (I) are useful in the treatment and / or prevention of premature labor, premature birth and dysmenorrhea. In particular, the present invention is related to pyrrolidine derivatives displaying a substantial modulatory, notably an antagonist activity of the oxytocin receptor. More preferably, said compounds are useful in the treatment and / or prevention of disease states mediated by oxytocin, including premature labor, premature birth and dysmenorrhea. The present invention is furthermore related to novel pyrrolidine derivatives as well as to methods of their preparation, wherein X is selected from the group consisting of CR6R7, NOR6, NNR6R7; A is selected from the group consisting of —(C═O)—, —(C═O)—O—, —C(═NH)—, —(C═O)—NH—, —(C═S)—NH, —SO22-, —SO2NH—, —CH2-, B is either a group —(C═O)—NR8R9 or represents a heterocyclic residue having the formula (a) wherein Q is NR10, O or S; n is an integer selected of 0, 1 or 2; Y, Z and E form together with the 2 carbons to which they are attached a 5–6 membered aryl or heteroaryl ring.

The invention provides sialic acid-added milk powder with an easy digestion function for premature infants and a preparation method thereof, and relates to the technical field of foods. The milk powder is prepared from the following raw materials: skim milk powder, lecithin, maltodextrin, immune globulin, refined palm olein, vitamin complex, prebiotics, minerals, alpha-whey protein, lactotransferrin, ferrous gluconate, bifidobacterium, sialic acid, edible vegetable oil mixture, beta-galactosidase, tryptophan, threonine and cystine. Compositions of the formula of the milk powder for premature infants is closer to breast milk, memory and intelligence level of premature infants can be improved by the sialic acid ingredient added into the milk powder, and nutrition essential to premature infant growth can be provided by optimizing the proportion of ingredients. The milk powder can be easily digested and absorbed, and can be used for improving the resistance of premature infants and reducing the phenomena of internal heat and iron-deficiency anemia caused by dyspepsia.

The present invention is related to piperazine-2-carboxamide derivatives of formula (I) for the treatment and / or prophylaxis of preterm labor, premature birth, dysmenorrhea and for stopping labor prior to cesarean delivery. Wherein A, X, Y, R1 and R2 are as defined in the description.

The present invention is related to the use of pyrrolidine esters of formula (I) for the treatment and / or prevention of premature labor, premature birth and dysmenorrhea. In particular, the present invention is related to the use of pyrrolidine esters of formula (I) to modulate, notably to antagonize the oxytocin receptor. The present invention is furthermore related to novel pyrrolidine esters. X is selected from the group consisting of CR6R7, NOR6, NNR6R7; R is selected from the group comprising or consisting of C1–C6 alkyl, C2–C6 alkenyl, C2–C6 alkynyl, saturated or unsaturated 3–8-membered cycloalkyl which may contain 1 to 3 heteroatoms selected of N, O, S, aryl, heteroaryl, C1–C6-alkyl aryl, C1–C6-alkyl heteroaryl. R1 is selected from the group comprising or consisting of C1–C6-alkyl, C2–C6-alkenyl, C2–C6-alkynyl, aryl, heteroaryl, 3–8-membered cycloalkyl, acyl, C1–C6-alkyl aryl, C1–C6-alkyl heteroaryl, said cycloalkyl or aryl or heteroaryl groups may be fused with 1–2 further cycloalkyl or aryl or heteroaryl group

A system and method for stabilizing an incontinent cervix during pregnancy are described. A system may include a nesting portion designed to surround the cervix without applying pressure to the cervix, while supporting the uterus in opposition to the weight of the developing fetus to prevent untimely effacement and dilatation of the cervix, thereby reducing the risk of premature birth and its consequence.

The present invention is related to the use of pyrrolidine esters of formula (I) for the treatment and / or prevention of premature labor, premature birth and dysmenorrhea. In particular, the present invention is related to the use of pyrrolidine esters of formula (I) to modulate, notably to antagonise the oxytocin receptor. The present invention is furthermore related to novel pyrrolidine esters. X is selected from the group consisting of CR6R7, NOR6, NNR6R7; R is selected from the group comprising or consisting of C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, saturated or unsaturated 3-8-membered cycloalkyl which may contain 1 to 3 heteroatoms selected of N, O, S, aryl, heteroaryl, C1-C6-alkyl aryl, C1-C6-alkyl heteroaryl. R1 is selected from the group comprising or consisting of C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, aryl, heteroaryl, 3-8-membered cycloalkyl, acyl, C1-C6-alkyl aryl, C1-C6-alkyl heteroaryl, said cycloalkyl or aryl or heteroaryl groups may be fused with 1-2 further cycloalkyl or aryl or heteroaryl group.

A system and method for stabilizing an incontinent cervix during pregnancy are described. A system may include a nesting portion designed to surround the cervix without applying pressure to the cervix, while supporting the uterus in opposition to the weight of the developing fetus to prevent untimely effacement and dilatation of the cervix; thereby reducing the risk of premature birth and its consequence.

The invention provides a neonatal infant incubator apparatus (10) and a control system module (17), and methods and systems for using the control system module to control the microenvironment of the contained space (16) of the infant incubator apparatus (10). The neonatal infant incubator apparatus (10) including a collapsible frame (12) and a disposable housing (14) to create a closed contained space (16) with a controlled microenvironment. The control system module (17) is comprises a battery (32) and is configured to operate with low voltage; the control system module (17) configured to control the microenvironment, including regulating the temperature and gas composition, of the contained space (16), and includes an air circulation system (72) in air and / or fluid communication with thecontained space (16). The systems, apparatus and methods are suitable for containing a full-term or premature infant in need of care in areas where power sources are limited, including e.g., rural orremote regions, third world countries, in a regular clinical setting and / or for transportation of the infant.

The present invention relates to triazole derivatives of formula (I) notably for use as pharmaceutically active compounds, as well as pharmaceutical formulations containing such triazole derivatives. Said triazoles are useful in the treatment and / or prevention of preterm labor, premature birth, dysmenorrhea, inappropriate secretion of vasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome and ocular hypertension. In particular, the present invention is related to triazole derivatives displaying a substantial modulatory, in particular antagonistic activity, of the oxytocin and / or vasopressin receptor. More preferably, said compounds are useful in the treatment and / or prevention of disease states mediated by oxytocin and / or vasopressin. The present invention is furthermore related to novel triazole derivatives as well as to methods of their preparation.

Respiratory Syncytial Virus is a common cold virus belonging to the family of paramyxovirus. RSV is virulent, easily transmissible and the most common cause of lower respiratory tract disease in children of less than 2 years of age. Up to 98% of children attending day care will be infected in a single RSV season. Between 0.5% and 3.2% of children with RSV infection require hospitalization. Approximately 90,000 hospital admissions and 4500 deaths per year were reported in United States. Major risk factors for hospitalization due to RSV are premature birth, chronic lung disease, congenital heart disease, compromised immunity, and age younger than 6 weeks in otherwise healthy children.

A system and method for stabilizing an incontinent cervix during pregnancy are described. A system may include a nesting portion designed to surround the cervix without applying pressure to the cervix, while supporting the uterus in opposition to the weight of the developing fetus to prevent untimely effacement and dilatation of the cervix, thereby reducing the risk of premature birth and its consequence.

The invention provides a nutrient, formula milk powder for a pregnant woman and application of the formula milk powder. The nutrient comprises numerous vitamins and multiple trace elements, so that requirements of the pregnant woman and a fetus on vitamins and trace elements can be met. The nutrient is characterized in that folic acid, iron and lactoferrin are simultaneously added to the nutrient, so that absorption of the pregnant woman to iron can be promoted, and anemia, caused by competition of the fetus for serum iron, of the pregnant woman can be improved. The formula milk powder comprises the nutrient, whey powder, whole milk powder, skimmed milk powder, prebiotics, lactoalbumin powder, calcium carbonate and maltodextrin. Various nutrient substances are scientifically matched, so that requirements of the pregnant woman and the fetus on various nutrient substances can be met; particularly, the folic acid, the iron and the lactoferrin are simultaneously added, so that the phenomenon of premature birth or underweight of the fetus caused by anemia of the pregnant woman can be effectively prevented.

Methods and devices to affect types, proportion, quantity, distribution, or proliferation of microorganisms within a female reproductive system.

The invention relates to a joint inspection kit for pregnant woman premature birth fetus fibronectin and phosphorylation insulin-like growth factor binding protein-1, and belongs to the technical field of inspection kits. The kit comprises a substrate, wherein a nitrocellulose membrane is arranged on one side of the substrate; a binding pad is arranged at the front end of the nitrocellulose membrane; a plurality of arrow tags are arranged at the rear end of the binding pad; a first non-transparent protection pad is arranged behind the arrow tags; a first detection line is arranged behind the first non-transparent protection pad; a mass control line is arranged behind the first detection line; a second first non-transparent protection pad is arranged at the rear end of the nitrocellulose membrane. A second detection line is further arranged between the first detection line and the mass control line. The kit is simple and convenient to apply, can be used for further improving the accuracy in premature birth diagnosis, and is applicable to large-scale popularization and application as joint inspection result provides a powerful basis for next accurate treatment.

The present invention is related to thiazolidine carboxamide derivatives of formula (II) for the treatment and / or prophylaxis of preterm labor, premature birth, dysmenorrhea and for stopping labor prior to cesarean delivery.

The present invention relates to sulfanilide derivatives of formula (I), in which R1 and R2 are optionally substituted aryl and heteroaryl groups and the other variables are as defined in the claims, for use as pharmaceutically active compounds, as well as pharmaceutical formulations containing such sulfanilide derivatives. Said derivatives are useful in the treatment and / or prevention of preterm labor, premature birth, dysmenorrhea, inappropriate secretion of vasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome and ocular hypertension. In particular, the present invention is related to sulfanilide derivatives displaying a substantial modulatory, in particular antagonistic activity, of the oxytocin and / or vasopressin receptor. More preferably, said compounds are useful in the treatment and / or prevention of disease states mediated by oxytocin and / or vasopressin, including preterm labor, premature birth, dysmenorrhea, inappropriate secretion of vasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome and ocular hypertension. The present invention is furthermore related to novel sulfanilide derivatives as well as to methods of their preparation.

The invention disclosed herein is a method for treatment of infants at risk for birth-related disabilities. Specifically, this disclosure is directed toward those infants at risk for neuromuscular disabilities caused by premature birth and / or injury during birth. An inflatable collar is affixed around the infant's neck. The infant wearing the aforementioned collar is immersed into a water bath in which the water has been heated to approximately 98.6 degrees Fahrenheit. The infant's head is supported by the inflated collar to ensure safe breathing. The infant's torso and extremities are suspended in the warm water bath. The infant is permitted to move in the water bath without being restrained by gravity. By the method disclosed herein, infants at risk for neuromuscular disabilities are permitted to exercise their muscles to develop muscle tone and promote neuromuscular coordination.

The present invention is related to thiazolidine carboxamide derivatives of formula (II) for the treatment and / or prophylaxis of preterm labor, premature birth, dysmenorrhea and for stopping labor prior to cesarean delivery. G is selected from the group consisting of C1-C6-alkyl aryl, C1-C6-alkyl heteroaryl, C1-C6 Alkyl cycloalkyl, C1-C6-alkyl heteroaryl, aryl, heteroaryl, C3-C8-cycloalkyl or -heterocycloalkyl, said cycloalkyl or aryl or hetetoaryl groups may be fused with cycloalkyl or aryl or heteroaryl groups. R1 is selected from the group consisting of aryl, heteroaryl, C3-C8-cycloalkyl or -heterocyclo-alkyl, said (hetero)cycloalkyl or aryl or heteroaryl groups may be fused with (hetero)cycloalkyl or aryl or heteroaryl groups. R2 is selected from the group consisting of H, carboxy, acyl, alkoxycarbonyl, aminocarbonyl, C1-C5-alkyl carboxy, C1-C5-alkyl acyl, C1-C5-alkyl alkoxycarbonyl, C1-C5-alkyl aminocarbonyl, C1-C5-alkyl acyloxy, C1-C5-alkyl acylamino, C1-C5-alkyl ureido, C1-C5alkyl amino, C1-C5-alkyl alkoxy, C1-C5-alkyl sulfanyl, C1-C5-alkyl sulfinyl, C1-C5-alkyl sulfonyl, C1-C5-alkyl sulfonylamino, C1-C5-alkyl sulfonyloxy, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, aryl, heteroaryl, C3-C8-cycloalkyl, heterocycloalkyl, C1-C6-alkyl aryl, C2-C6-alkyl heteroaryl, C1-C6-alkyl cycloalkyl, C1-C6-alkyl heterocycloalkyl, C2-C6-alkenyl aryl, C2-C6-alkenyl heteroaryl, C2-C6-alkynyl aryl, or C2-C6-alkynyl heteroaryl.

The invention discloses disposable warm-keeping clothes for a premature birth newborn. The warm-keeping clothes comprise a collar, a right side piece, a left side piece and a middle piece, wherein the collar, the right side piece, the left side piece and the middle piece are made of transparent airtight materials. The warm-keeping clothes are simple in structure; when in use, the warm-keeping clothes can be conveniently put on the premature birth newborn in a conventional way; and meanwhile, the warm-keeping clothes adopt a conveniently opened or closed structure, so that the premature birth newborn can be conveniently subjected to resuscitation-related measures such as tracheal intubation, external chest compression, vein opening and the like and examinations by a doctor. In addition, the warm-keeping clothes are made of the transparent airtight materials, so that the warm-keeping performance is greatly improved; and meanwhile, due to the transparency, the doctor can monitor the premature birth newborn without interference.